NASDAQ:BIOC - Biocept Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biocept Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.34 -0.01 (-2.84 %) (As of 01/23/2020 09:29 AM ET) Add Compare Today's Range$0.33Now: $0.34▼$0.3550-Day Range$0.24MA: $0.32▼$0.5952-Week Range$0.23Now: $0.34▼$2.50Volume3.73 million shsAverage Volume11.64 million shsMarket Capitalization$16.29 millionP/E RatioN/ADividend YieldN/ABeta1.56 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOC Previous Symbol CUSIPN/A CIK1044378 Webhttp://www.biocept.com/ Phone858-320-8200Debt Debt-to-Equity Ratio0.13 Current Ratio1.83 Quick Ratio1.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.25 million Price / Sales5.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book0.52Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-24,570,000.00 Net Margins-552.54% Return on Equity-268.76% Return on Assets-156.38%Miscellaneous Employees95 Outstanding Shares47,620,000Market Cap$16.29 million Next Earnings Date3/26/2020 (Estimated) OptionableOptionable Receive BIOC News and Ratings via Email Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BIOC Rates by TradingView Biocept (NASDAQ:BIOC) Frequently Asked Questions What is Biocept's stock symbol? Biocept trades on the NASDAQ under the ticker symbol "BIOC." How were Biocept's earnings last quarter? Biocept Inc (NASDAQ:BIOC) announced its quarterly earnings results on Wednesday, November, 13th. The medical research company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02. The medical research company had revenue of $1.53 million for the quarter. Biocept had a negative net margin of 552.54% and a negative return on equity of 268.76%. View Biocept's Earnings History. When is Biocept's next earnings date? Biocept is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Biocept. What price target have analysts set for BIOC? 1 Wall Street analysts have issued 12 month target prices for Biocept's shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Biocept's stock price to reach $1.00 in the next twelve months. This suggests a possible upside of 192.4% from the stock's current price. View Analyst Price Targets for Biocept. What is the consensus analysts' recommendation for Biocept? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept. What are Wall Street analysts saying about Biocept stock? Here are some recent quotes from research analysts about Biocept stock: 1. Maxim Group analysts commented, "Biocept reported 1Q19 with ~$1M in revenue and a net loss of $5.9M. The company ended the period with $14.8M in cash on the balance sheet." (5/9/2019) 2. According to Zacks Investment Research, "Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. " (2/13/2019) Has Biocept been receiving favorable news coverage? Media headlines about BIOC stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biocept earned a daily sentiment score of 1.6 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Biocept. Who are some of Biocept's key competitors? Some companies that are related to Biocept include Psychemedics (PMD), PotNetwork (POTN), Miragen Therapeutics (MGEN), Avant Diagnostics (AVDX), OpGen (OPGN), CBA Florida (CBAI), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC). What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include Walmart (WMT), AVEO Pharmaceuticals (AVEO), Kadmon (KDMN), Advanced Micro Devices (AMD), SCYNEXIS (SCYX), Actinium Pharmaceuticals (ATNM), Onconova Therapeutics (ONTX), Aurora Cannabis (ACB), VBI Vaccines (VBIV) and Chesapeake Energy (CHK). Who are Biocept's key executives? Biocept's management team includes the folowing people: Mr. Michael W. Nall, CEO, Pres & Director (Age 56)Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)Dr. Soon Kap Hahn Ph.D., FounderMr. Pavel Tsinberg, Director of Technology Devel. How do I buy shares of Biocept? Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Biocept's stock price today? One share of BIOC stock can currently be purchased for approximately $0.34. How big of a company is Biocept? Biocept has a market capitalization of $16.29 million and generates $3.25 million in revenue each year. Biocept employs 95 workers across the globe.View Additional Information About Biocept. What is Biocept's official website? The official website for Biocept is http://www.biocept.com/. How can I contact Biocept? Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected] MarketBeat Community Rating for Biocept (NASDAQ BIOC)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 293 (Vote Outperform)Underperform Votes: 316 (Vote Underperform)Total Votes: 609MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2020 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?
